A federal advisory panel voted on July 23, 2026 to recommend that compounding pharmacies in the United States be allowed to make four unapproved peptides: BPC-157, KPV, TB-500 and MOTS-c. The FDA’s Pharmacy Compounding Advisory Committee backed BPC-157, KPV and TB-500 by 8 to 6 with one abstention, and MOTS-c by 7 to 5 with two abstentions, according to Pharmaceutical Executive’s tally of the meeting.
The panel voted that way after FDA’s own scientists told them not to. In its briefing document for the meeting, the agency proposed that every one of the seven peptides on the two-day agenda be kept off the list. The votes are advisory only. FDA makes the final call.
Key takeaways
- The votes recommend adding these peptides to the Section 503A Bulks List, which is a permission to compound, not a finding that the drugs work.
- FDA reviewers proposed rejecting all seven peptides. The panel overruled them on six of the seven, per NPR.
- Nothing changes today. Any change runs through formal rulemaking that could take many months.
What happened
The Pharmacy Compounding Advisory Committee met at FDA’s White Oak campus in Silver Spring, Maryland on July 23 and 24. Per the FDA meeting notice, the agency reviewed each peptide for a narrow use: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, and MOTS-c for obesity and osteoporosis.
FDA’s briefing document is blunt. For each substance it states a version of the same line, including “FDA is proposing that BPC-157 (free base) NOT be included on the 503A Bulks List.” The same proposal appears for KPV, TB-500, MOTS-c, Emideltide, Epitalon and Semax.
NPR reported that FDA scientists “spoke extensively about the lack of reliable data for any of the seven peptides” and that in some cases they could not find any published human clinical studies at all. FDA official Russell Wesdyk described a more basic problem, telling the panel, “We can’t create quality standards until we actually know what it is.”
The committee recommended six of the seven peptides. Only Emideltide, sometimes used for insomnia, got a no vote, NPR reported.
The panel’s makeup drew criticism. NPR reported that eight new members were appointed ahead of the meeting and that “Most have ties to the peptide industry.” An HHS spokesperson said all members went through the standard ethics and vetting process.
Dr. Kumar’s take
Here is the part I think gets lost. Being on the 503A Bulks List is a supply chain permission. It means a licensed compounding pharmacy may legally use the raw substance. It is not an FDA finding that the drug is safe, and it is not a finding that it works. Approval requires large controlled human trials. That did not happen here and nobody claims it did.
BPC-157 is the one patients ask me about most, usually for a stubborn tendon or a slow surgical recovery. Its reputation rests almost entirely on rodent studies. ABC News noted that most of the work so far has been in rodents, and rodent healing results have a long history of not holding up in people. Compare that to something like creatine, which has decades of human safety data behind it and position statements built on trials. Peptides are nowhere near that.
Three unknowns worry me specifically as a surgeon. First, several of these compounds are promoted for their effects on blood vessel growth, and NPR reported FDA raised concerns about “the potential to encourage cancer growth.” If you have a cancer history, that is not a small footnote. Second, there is no long-term human dosing data, so nobody can tell you what a year of use does. Third, FDA could not always define the molecule itself. A panel member who voted no on KPV put it plainly: “I’m voting on something here, but I don’t know what that something is.”
The conflict of interest issue is real too. A panel stacked with people who run peptide clinics voting to overrule the agency’s career reviewers is a process problem, whatever you think of the peptides.
What it means for you
Nothing is legal to buy tomorrow that was not legal yesterday. If FDA follows the recommendation, it goes through formal rulemaking, which NPR reported could stretch into next year or 2028.
If a clinic tells you this vote means BPC-157 is now FDA cleared or FDA approved, that is wrong, and I would take it as a signal about the clinic. If you are considering these drugs anyway, tell your surgeon and your oncologist, and understand you are the experiment. The honest summary is that the country may soon get a cleaner supply of compounds nobody can say much about yet.